Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMU-132 Alone or with Carboplatin in TNBC
NCT02161679Phase 2Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Aug 2016
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, randomised, open-label trial of sacituzumab govitecan in triple-negative breast cancer (TNBC) (2 arms), sponsored by Gilead Sciences. Primary endpoints: Progression Free Survival at 2 years and Safety and Efficacy. Planned start Aug 2016; status: withdrawn.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02161679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161679.